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Purpose of the study
To assess the safety and efficacy of tipranavir co-adminis-
tered with low-dose ritonavir (TPV/r) in clinical settings.
Methods
Data from the German open-label study (EAP). To be
included in the study, adult patients (pts) had to be triple
antiretroviral (ARV) class experienced having failed at
least two previous PI-based regimens. TPV/r 500/200 mg,
twice daily, was added to a background regimen chosen
by the treating physician. All adverse events (AE) were
reported regardless of causal relationship and degree of
seriousness.
Summary of results
Data of 254 HIV-1 infected pts (median age 44 years; 229
males, 25 females) from 70 centres were available for
analysis. Most pts were in advanced stages: CDC B3 (28%)
and C3 (57.1%). Hepatitis B and C co-infection was
reported for 12.6% and 3.9% of the pts, respectively.
Median baseline HIV-RNA (VL) was 4.7 log10 copies/mL
and median CD4157 cells/μL. After 12 months of TPV/r
treatment, median change from baseline in VL was -1.9
log10 copies/mL and +71.5 CD4 cells/μL. Median TPV/r
exposure was 35.4 weeks (1.1–76). 117 (46.1%) pts expe-
rienced AEs considered related to TPV/r; 53 (20.9%) pts
developed serious AEs; 47 (18.5%) pts discontinued TPV/
r due to AEs. Most commonly reported AEs in 33.5% of
pts were gastrointestinal disorders, the majority of which
were mild or moderate intensity. In regard to ALT and AST
elevations, 4.3% and 2% of pts had a maximum Grade 3
and 3.1% and 0.2% of pts had maximum Grade 4 eleva-
tion, respectively. No cases of jaundice or liver failure were
reported.
Conclusion
Patients treated in the TPV EAP had advanced HIV-1 infec-
tion and were heavily pretreated. Nevertheless, they show
remarkable decrease in VL and increase in CD4 cells/μL
The analysis of AEs did not reveal any new safety findings
or change in the known AE profile of TPV/r. Notably, in
this real world treatment setting, the rate of TPV/r discon-
tinuations due to AEs was relatively low.
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